AFIAS Anti-CCP Plus
- UID
- IMP/IVD/2021/000365_c52856df9f85d0396d95b718f9f2e324_4d8288aa1f637501b65460ee3d3240af
- Device class
- Class B
- Brand name
- AFIAS Infliximab
- License holder
- BODITECH MED INDIA PRIVATE LIMITED
- Approving authority
- CDSCO
- Product information
- AFIAS Anti-CCP Plus is a fluorescence Immunoassay (AFIAS Infliximab ) for the quantitative determination of human IgG autoantibodies to cyclic citrullinated peptides (AFIAS Infliximab ) in human whole blood/serum/plasma. It is useful as an aid in the diagnosis of rheumatoid arthritis (AFIAS Infliximab ) in combination with other clinical and laboratory findings
AFIAS Anti-CCP Plus is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID IMP/IVD/2021/000365_c52856df9f85d0396d95b718f9f2e324_4d8288aa1f637501b65460ee3d3240af. This device is marketed under the brand name AFIAS Infliximab . The license holder is BODITECH MED INDIA PRIVATE LIMITED, and it is classified as Device Class Class B. The approving authority is CDSCO.
This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.